August 27, 2016 7:31 PM ET

Biotechnology

Company Overview of Osel Inc.

Company Overview

Osel Inc., a clinical stage biopharmaceutical company, develops proprietary technology platform of live biotherapeutic products for the treatment and prevention of conditions impacting women’s health, gastrointestinal disorders, and infectious diseases through modulation of the Human Microbiome. It provides LACTIN-V, a safety profile and is accepted and tolerated by the study populations; MIYA-BM, an orally-administered LBP that is based on a bacterial strain safely; and MucoCept, which involves the use of proprietary technology designed to harness the Human Microbiome. The company was founded in 1996 and is based in Mountain View, California.

320 Logue Avenue

Mountain View, CA 94043

United States

Founded in 1996

Phone:

650-964-1420

Fax:

650-964-4679

Key Executives for Osel Inc.

Founder, Chairman and Chief Executive Officer
President
Age: 67
Scientific Co-Founder
Scientific Co-Founder
Age: 57
Scientific Co-Founder
Compensation as of Fiscal Year 2016.

Osel Inc. Key Developments

Osel, Inc. Comments on New Study Showing Role of Vaginal Microbiome in Women’S Health

Osel Inc. commented on findings presented by the Centre for the AIDS Programme of Research in South Africa (CAPRISA [2]) consortium of South African and North American researchers at the International AIDS 2016 Conference, detailing the role played by vaginal dysbiosis in the high rates of sexual transmission of HIV to women from men. The researchers found that an imbalance of certain bacteria in the vagina was associated with both higher transmission of HIV and a reduction in the efficacy of an antiviral drug used to prevent HIV infection. In their presentation, the scientists concluded that an important step in preventing the spread of HIV infection is restoring and maintaining a healthy vaginal microbiome in those affected by vaginal dysbiosis. The CAPRISA study highlights the critical role that a healthy vaginal microbiome plays in protecting women from bacterial and viral infection, and stresses the need for an effective solution to vaginal dysbiosis. Currently the only FDA-approved treatments for a prevalent vaginal dysbiosis, called bacterial vaginosis, are antibiotics. These antibiotics do interfere with the unwanted pathogenic bacteria, but do not address the underlying problem of low vaginal Lactobacillus levels.

Similar Private Companies By Industry

Company Name Region
20n Labs, Inc. United States
23andMe, Inc. United States
2C Tech Corporation, Inc. United States
3-V Biosciences, Inc. United States
3D Bio Holdings LLC United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

The information and data displayed in this profile are created and managed by Capital IQ, a Standard & Poor's company. Bloomberg.com does not create or control the content. For inquiries, please contact Capital IQ directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
The Advertising Council, Inc. United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Osel Inc., please visit www.oselinc.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.